Akaishi, Tetsuya
Misu, Tatsuro
Fujihara, Kazuo
Nakaya, Naoki
Nakamura, Tomohiro
Kogure, Mana
Hatanaka, Rieko
Itabashi, Fumi
Kanno, Ikumi
Takahashi, Toshiyuki
Kuroda, Hiroshi
Fujimori, Juichi
Takai, Yoshiki
Nishiyama, Shuhei
Kaneko, Kimihiko
Ishii, Tadashi
Aoki, Masashi
Nakashima, Ichiro
Hozawa, Atsushi
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (20FC1030)
Japan Society for the Promotion of Science (20K07892)
Article History
Received: 3 July 2021
Accepted: 8 November 2021
First Online: 16 November 2021
Competing interests
: K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria and travel funding from Mitsubishi Tanabe Pharma, Biogen Japan, and Novartis Pharmaceuticals and received research support from LSI Medience Corporation. The remaining authors don’t have any conflict of interest.